Rallybio (RLYB) Company Sales Revenue

Rallybio Corp - graphic logo of issuer RLYB

Rallybio Corporation (RLYB) operates in the underserved orphan disease therapy segment, where demand is critically high. The business's success is based on patents and the results of fetal treatment trials. The robotization of research accelerates data analysis, which is reflected in the company's sales chronology through revenue dynamics. The current value of 0.00 shows the actual metric value, helping to filter out market noise from real income.

Rallybio Corp. (RLYB) - Revenue and Sales Volume from 07/04/2022 to 11/17/2026

Analytical breakdowns for Rallybio Corporation

- market price and analyst price targets:
General company analysis:RLYB (Rallybio)
Brand item of Rallybio Corp.

Fundamental screening of a defensive portfolio requires confirming the issuer's resilience through an analysis of actual cash inflows. This indicator captures actual daily receipts from customers, allowing for an assessment of current liquidity and the business's operational strength. For Rallybio Corporation (RLYB), as a developer of rare disease therapies, the absence of revenue coupled with high research expenditures highlights a critical dependence on external capital. The dynamics of Rallybio Corporation (RLYB) product realization clearly demonstrate the financial risks associated with clinical trial stages.

Key competitors

HLN: Company Sales Revenue|Company Revenue Kenvue (KVUE)|VRNA (Verona Pharma Corp) - Company Sales Revenue|Company Revenue Jyong Biotech MENS|Ligand Pharma - Company Revenue|AMRX - Company Revenue|Company Total Revenue perrigo.com|ALVO (Alvotech SA) - Company Sales|Company Total Sales Volume Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Revenue and Sales Volume|ANIP: Company Sales Revenue|Company Revenue Afrezza (MNKD)|Revenue and Sales Volume amphastar.com (AMPH)|Revenue and Sales Volume PCRX (pacira.com)|Company Sales Revenue SPRY|Theravance Biopharma Inc - Revenue and Sales Volume|Company Gross Revenue Aquestive Therapeutics AQST|SCPH: Revenue and Sales Volume|Company Sales Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Revenue and Sales Volume|SXTC (China SXT Pharmaceuticals, Inc.) - Company Total Sales|Company Revenue eupraxiapharma.com (EPRX)|Company Total Sales BHST|Company Revenue eXoZymes EXOZ|Company Sales Revenue ORMP|ENTX - Company Revenue|HYFT: Company Revenue|ABVC BioPharma, Inc (ABVC) - Company Revenue|Cumberland Pharma - Company Sales Revenue|QNTM (Quantum BioPharma Corp) - Revenue and Sales Volume|FibroGen, Inc. - Company Annual Revenue|Revenue and Sales Volume TELO|Company Gross Revenue Rani Therapeutics Holdings, Inc.|Company Revenue Synergy CHC Corp. SNYR|LEXX: Company Sales Volume|PULM - Company Revenue|PTHL: Company Revenue|APM (aptorumgroup.com) - Company Sales|Lyra Therapeutics - Company Sales Revenue|Company Revenue Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Company Gross Revenue|Revenue and Sales Volume YCBD|PRFX: Company Annual Revenue|Company Revenue altamiratherapeutics.com CYTO|Revenue and Sales Volume Lipella Pharmaceuticals Inc LIPO|OPTN - Company Revenue|Company Gross Revenue Pieris Pharma PIRS|Procaps Group SA (PROC) - Company Revenue|Company Annual Revenue PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding) - Revenue and Sales Volume|SLRN: Company Sales Revenue|Revenue and Sales Volume TFFP